Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis
PLOS One · 10.07.2026 · 21 (7) · e0352863
DOI: 10.1371/journal.pone.0352863 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 10.07.2026. Verfasst von Athira Thankamani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellor…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Machine Learning, Mutation, Drug Resistance, Bacterial. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis is a deadly airborne disease caused by Mycobacterium tuberculosis . Drug-resistant tuberculosis presents significant challenges for treatment and control of the disease. Resistant strains of Mycobacterium tuberculosis arise from specific mutations in the bacterium. Identification and characterization of resistance-associated mutations are crucial for effective treatment strategies because the first- and second-line drugs for the disease target distinct genes in the bacterium and serve different purposes. Our study developed a machine learning prediction model to analyze mutations across multiple drug-resistance types. The proposed framework predicts drug-resistance mutations across four drug-resistance types, including Rifampicin Resistance, Isoniazid Resistance, Multidrug Resistance, and Pre-extensively Drug-Resistant tuberculosis. The NIAID-NIH TB portal is a publicly available dataset of tuberculosis patients, including drug-resistance information. Our study analyzed 3,065 cases of drug-resistant TB. Eight supervised ML algorithms were implemented for the study. A Random Forest classifier with 10-fold cross-validation shows higher predictive performance than the other seven algorithms considered for further analysis. Significant drug resistance mutations were identified using SHapley Additive exPlanations feature importance. The World Health Organisation mutation catalogues, considered the gold standard for drug-resistant mutations, were used to evaluate prediction results. Mutations not reported in the WHO catalogues were identified during the post-prediction comparative analysis stage, as they may represent potential resistance-conferring markers warranting further investigation, including structural and functional validation or experimental validation. The mutations are rpoB- I480T, rpoC -G332R, L527V, gyrA -D94V, KatG -G99E, A106V, W191R, W328C, T380I, and M420T. The study further checks the stability and pathogenicity of the mutations using computational tools, including I-Mutant 2.0 and PredictSNP. The findings added more clarity and further evidence for the significance of the mutation, based on its contribution to drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
- Department of Analytics, School of Computer Science and Engineering, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
ORCID-Profile: Athira Thankamani, George Priya Doss C
Zitieren
APA
Thankamani, A., C L, B., & Doss C, G. P. (2026). Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis. PLOS One, 21(7), e0352863. https://doi.org/10.1371/journal.pone.0352863
Vancouver
Thankamani A, C L B, Doss C GP. Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis. PLOS One. 2026;21(7):e0352863. doi:10.1371/journal.pone.0352863
BibTeX
@article{Thankamani2026,
author = {Thankamani, Athira and C L, Biji and Doss C, George Priya},
title = {Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352863},
doi = {10.1371/journal.pone.0352863}
}
EUVIMED